Humacyte, Inc. (NASDAQ:HUMA) is one of the penny stocks with potential to rise 1000 percent.
On March 27, 2026, BTIG maintained its Buy rating on Humacyte but cut its price target to $3 from $6 after the company reported fourth-quarter and full-year 2025 results earlier the same day. Humacyte reported $0.5 million in fourth-quarter revenue and $2.0 million in full-year revenue, while BTIG said the quarterly figure missed its $1.3 million estimate. The analyst note also said the company posted a loss per share of $0.13, versus consensus expectations for a $0.12 loss.
BTIG said the trauma launch for Symvess remains choppy on a quarter-to-quarter basis. The firm noted that Humacyte sold about 25 units in the fourth quarter, down from about 29 in the third quarter of 2025, while the price per unit declined to roughly $17,000 from about $24,500. BTIG also flagged elevated operating expenses and said cash remains a critical focus.
Even so, BTIG pointed to some commercial progress, with the number of hospitals ordering Symvess for trauma use rising to 27 from 16. Humacyte also said on March 27 that it received a purchase commitment for a minimum of $1.475 million for a clinical evaluation and outreach program in Saudi Arabia, while both the company and BTIG highlighted interim top-line results from the Phase 3 V012 study in dialysis access expected in the second quarter of 2026. BTIG said the dialysis access market represents a larger opportunity than the trauma market.
Humacyte, Inc. (NASDAQ:HUMA) is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale.
While we acknowledge the potential of HUMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
Disclaimer : This story is auto aggregated by a computer programme and has not been created or edited by DOWNTHENEWS. Publisher: finance.yahoo.com
